Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLGN CollPlant Biotechnologies	$2.40 +22.0%	$1.97	$1.31 ▼ $5.45	$30.53M	1.47	57,236 shs	106,681 shs
POAI Predictive Oncology	$0.92 +1.8%	$0.83	$0.55 ▼ $3.06	$9.98M	1.18	1.93 million shs	58,984 shs
POCI Precision Optics	$4.64 -2.3%	$4.75	$3.47 ▼ $6.59	$35.57M	0.3	15,099 shs	1,429 shs
TMDIF Titan Medical	$0.33	$0.32	$0.03 ▼ $1.00	$37.09M	1.26	74,785 shs	27 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLGN CollPlant Biotechnologies	-19.92%	-27.57%	-12.05%	+0.25%	-60.60%
POAI Predictive Oncology	0.00%	+3.45%	+14.62%	-8.16%	-1.59%
POCI Precision Optics	+2.15%	+2.15%	-1.25%	+8.45%	-7.77%
TMDIF Titan Medical	0.00%	-11.73%	-14.50%	-0.20%	+693.17%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CLGN CollPlant Biotechnologies	2.59 of 5 stars	3.5	5.0	0.0	0.0	1.4	0.0	0.6
POAI Predictive Oncology	0.3527 of 5 stars	0.0	3.0	0.0	0.0	1.4	0.0	0.6
POCI Precision Optics	0.1124 of 5 stars	0.0	3.0	0.0	0.0	0.0	0.8	0.0
TMDIF Titan Medical	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CLGN CollPlant Biotechnologies	3.00	Buy	$11.50	379.17% Upside
POAI Predictive Oncology	2.00	Hold	N/A	N/A
POCI Precision Optics	0.00	N/A	N/A	N/A
TMDIF Titan Medical	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest POAI, TMDIF, POCI, and CLGN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/21/2025	CLGN CollPlant Biotechnologies	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$11.00
8/20/2025	CLGN CollPlant Biotechnologies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00
5/28/2025	CLGN CollPlant Biotechnologies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$14.00 ➝ $12.00

(Data available from 8/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CLGN CollPlant Biotechnologies	$510K	59.86	N/A	N/A	$1.18 per share	2.03
POAI Predictive Oncology	$1.62M	6.16	N/A	N/A	($0.15) per share	-6.11
POCI Precision Optics	$17.63M	2.02	N/A	N/A	$1.66 per share	2.80
TMDIF Titan Medical	$17.63M	2.10	$16.26 per share	0.02	$1.05 per share	0.31

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CLGN CollPlant Biotechnologies	-$16.61M	-$1.22	N/A	N/A	N/A	-560.92%	-87.33%	-65.31%	11/3/2025 (Estimated)
POAI Predictive Oncology	-$12.66M	-$3.05	N/A	N/A	N/A	-587.31%	-722.01%	-167.23%	N/A
POCI Precision Optics	-$2.95M	-$0.89	N/A	∞	N/A	-32.84%	-54.03%	-32.48%	9/29/2025 (Estimated)
TMDIF Titan Medical	$6.95M	$0.05	N/A	∞	N/A	N/A	-82.31%	-51.47%	N/A

Latest POAI, TMDIF, POCI, and CLGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/20/2025	Q2 2025	CLGN CollPlant Biotechnologies	$0.29	-$0.28	-$0.57	-$0.28	$8.91 million	$0.18 million
8/13/2025	Q2 2025	POAI Predictive Oncology	-$0.09	-$0.22	-$0.13	-$0.23	$1.50 million	$0.00 million
6/4/2025	Q1 2025	CLGN CollPlant Biotechnologies	-$0.37	-$0.13	+$0.24	-$0.13	$9.76 million	$2.06 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CLGN CollPlant Biotechnologies	N/A	N/A	N/A	N/A	N/A
POAI Predictive Oncology	N/A	N/A	N/A	N/A	N/A
POCI Precision Optics	N/A	N/A	N/A	N/A	N/A
TMDIF Titan Medical	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CLGN CollPlant Biotechnologies	N/A	4.48	4.23
POAI Predictive Oncology	N/A	0.32	0.31
POCI Precision Optics	0.11	1.99	1.26
TMDIF Titan Medical	N/A	3.73	3.73

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CLGN CollPlant Biotechnologies	21.69%
POAI Predictive Oncology	9.04%
POCI Precision Optics	13.71%
TMDIF Titan Medical	0.03%

Insider Ownership

Company	Insider Ownership
CLGN CollPlant Biotechnologies	9.60%
POAI Predictive Oncology	3.44%
POCI Precision Optics	12.99%
TMDIF Titan Medical	0.02%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CLGN CollPlant Biotechnologies	70	12.72 million	11.50 million	Optionable
POAI Predictive Oncology	30	10.89 million	10.52 million	Not Optionable
POCI Precision Optics	80	7.67 million	6.67 million	Not Optionable
TMDIF Titan Medical	50	114.04 million	4.56 million	Not Optionable

POAI, TMDIF, POCI, and CLGN Headlines

Recent News About These Companies

Titan Medical Group Launches Titan Workforce Solutions: Launches to Transform Healthcare Staffing

April 29, 2025 | businesswire.com

Titan Nurse Staffing, LLC and Titan Medical Group, LLC Announce Merger to Streamline Healthcare Staffing Services

April 29, 2025 | businesswire.com

Titan MRI acquires High Field MRI, expanding Titan MRI's service to North Central Florida

December 3, 2024 | msn.com

Attack on Titan movie release date, trailer, changes, and everything else we know about The Last Attack

November 6, 2024 | gamesradar.comG

Conavi Medical Corp. (formerly “Titan Medical Inc.”) Completes Business Combination

October 11, 2024 | globenewswire.com

Titan Announces the Closing of Conavi's Private Placement of Subscription Receipts and Provides Update on the Transaction

October 8, 2024 | globenewswire.com

Titan Announces Resignations of Directors

October 2, 2024 | globenewswire.com

Titan Reports Voting Results from 2023 Annual General and Special Meeting

September 30, 2024 | globenewswire.com

Titan Medical begins process to move to the TSX Venture Exchange

September 30, 2024 | globenewswire.com

Conavi Medical Shareholders Approve the Proposed Amalgamation Between Titan and Conavi

September 26, 2024 | globenewswire.com

Proxy Deadline Thursday September 26, 2024

September 25, 2024 | globenewswire.com

Proxy Advisor Glass, Lewis & Co., Recommends Titan Shareholders Vote FOR the Amalgamation Between Titan and Conavi

September 19, 2024 | globenewswire.com

A key employee says the Titan sub tragedy could have been prevented

September 18, 2024 | postregister.comP

Titan Announces Conavi Medical to Present Overview at Titan Q&A Session

September 16, 2024 | globenewswire.com

Independent Proxy Advisor, Institutional Shareholder Services (“ISS”), Recommends Titan Shareholders Vote FOR the Amalgamation Between Titan and Conavi

September 16, 2024 | globenewswire.com

Titan Announces Q&A Session with Shareholders

September 9, 2024 | globenewswire.com

Titan Announces Filing of the Management Information Circular.

September 6, 2024 | globenewswire.com

Titan Medical | Morning Blend

September 3, 2024 | msn.com

Titan Medical Inc. (QTNA.SG)

August 24, 2024 | finance.yahoo.com

Titan Medical Reports Operating and Financial Results for the Second Quarter 2024

August 15, 2024 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

POAI, TMDIF, POCI, and CLGN Company Descriptions

CollPlant Biotechnologies NASDAQ:CLGN

$2.40 +0.43 (+22.01%)

Closing price 04:00 PM Eastern

Extended Trading

$2.37 -0.03 (-1.25%)

As of 05:39 PM Eastern

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds; as well as develops injectable breast implants and 3D bioprinted regenerative soft tissue matrix for use in breast reconstruction procedures. It has collaboration agreements with Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; International Society for Biofabrication; AbbVie; and STEMCELL Technologies. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. The company was founded in 2004 and is headquartered in Rehovot, Israel.

Predictive Oncology NASDAQ:POAI

$0.92 +0.02 (+1.78%)

Closing price 04:00 PM Eastern

Extended Trading

$0.90 -0.01 (-1.20%)

As of 06:14 PM Eastern

Predictive Oncology Inc. operates as a science-driven company on the oncology drug discovery. It provides various solutions for the oncology drug development. The company, through the integration of scientific rigor and machine learning, has developed the ability to advance molecules into medicine by introducing human diversity earlier into the discovery process with the pairing of artificial intelligence and the biobank of approximately 150K tumor samples. It operates through four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment provides services that include the application of AI, collaboration projects, and clinical testing. The zPREDICTA segment develops organ-specific disease models that provide 3D reconstruction of human tissues representing each disease state and mimicking drug response for testing of anticancer agents. The Soluble segment provides services using a self-contained automated system that conducts self-interaction chromatography screens using additives and excipients included in protein formulations resulting in soluble and physically stable formulations for biologics. This segment also offers protein stability analysis services; protein solubility kits that allow rapid identification of soluble formulations; and proprietary technologies for bacterial endotoxin detection and removal. The Skyline segment provides STREAMWAY System, a wall-mounted fully automated system, which virtually eliminates exposure to blood, irrigation fluid, and other infectious fluids found in the healthcare environment. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is headquartered in Eagan, Minnesota.

Precision Optics NASDAQ:POCI

$4.67 -0.08 (-1.68%)

As of 04:00 PM Eastern

Precision Optics Corporation, Inc. designs, develops, manufactures, and sells specialized optical and illumination systems and related components primarily in the United States and the European Economic Area. It offers medical instrumentation products, including endoscopes and endocouplers, as well as other custom imaging and illumination products, such as Microprecision lenses and micro medical cameras, and 3D endoscopes for use in minimally invasive surgical procedures by hospitals and physicians. The company also provides components and assemblies for industrial and military use. It markets its products to medical device companies. The company was incorporated in 1982 and is based in Gardner, Massachusetts.

Titan Medical NASDAQ:TMDIF

$0.33 0.00 (0.00%)

As of 08/19/2025

Titan Medical Inc. operates as a medical technology company. It focuses on the development and licensing of robotic assisted surgical technologies. The company is headquartered in Toronto, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time